Published in FEMS Immunol Med Microbiol on October 03, 2011
Pertussis. A reemerging and an underreported infectious disease. Saudi Med J (2014) 0.80
Bordetella parapertussis survives the innate interaction with human neutrophils by impairing bactericidal trafficking inside the cell through a lipid raft-dependent mechanism mediated by the lipopolysaccharide O antigen. Infect Immun (2012) 0.79
Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog (2005) 2.71
Multiple-locus variable-number tandem repeat analysis of Dutch Bordetella pertussis strains reveals rapid genetic changes with clonal expansion during the late 1990s. J Bacteriol (2004) 2.58
Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis (2009) 2.36
Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis (2010) 2.20
Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J Clin Microbiol (2002) 2.02
Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis (2007) 1.77
Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio (2014) 1.76
Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis (2003) 1.73
Bordetella holmesii DNA is not detected in nasopharyngeal swabs from Finnish and Dutch patients with suspected pertussis. J Med Microbiol (2006) 1.69
Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J (2008) 1.69
Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS One (2010) 1.61
Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland. Clin Vaccine Immunol (2012) 1.50
Changes in the Dutch Bordetella pertussis population in the first 20 years after the introduction of whole-cell vaccines. Microbiology (2002) 1.46
Bordetella pertussis strain variation and evolution postvaccination. Expert Rev Vaccines (2009) 1.38
Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microbes Infect (2005) 1.36
Small mutations in Bordetella pertussis are associated with selective sweeps. PLoS One (2012) 1.35
Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics (2010) 1.33
Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants? J Infect Dis (2003) 1.29
Strain variation among Bordetella pertussis isolates in finland, where the whole-cell pertussis vaccine has been used for 50 years. J Clin Microbiol (2005) 1.28
Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genomics (2008) 1.26
Comparative genomics of Bordetella pertussis reveals progressive gene loss in Finnish strains. PLoS One (2007) 1.26
Pertussis in the Netherlands, is the current vaccination strategy sufficient to reduce disease burden in young infants? Vaccine (2013) 1.24
Pathogen adaptation under imperfect vaccination: implications for pertussis. Proc Biol Sci (2005) 1.24
Oral human papillomavirus infection in HIV-negative and HIV-infected MSM. AIDS (2013) 1.13
Improving pertussis vaccination. Hum Vaccin (2009) 1.12
Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infect Immun (2008) 1.09
Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains. Clin Vaccine Immunol (2007) 1.05
Bordetella pertussis, Finland and France. Emerg Infect Dis (2006) 1.05
Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol (2007) 1.04
Population dynamics of Bordetella pertussis in Finland and Sweden, neighbouring countries with different vaccination histories. Vaccine (2006) 1.04
Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin (2006) 1.03
The seroepidemiology of immunoglobulin G antibodies against pertussis toxin in China: a cross sectional study. BMC Infect Dis (2012) 1.03
Bordetella pertussis clones identified by multilocus variable-number tandem-repeat analysis. Emerg Infect Dis (2010) 1.03
Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs. Vaccine (2011) 1.03
Bordetella pertussis isolates in Finland: serotype and fimbrial expression. BMC Microbiol (2008) 1.02
Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model. Vaccine (2004) 1.02
Differences in the genomic content of Bordetella pertussis isolates before and after introduction of pertussis vaccines in four European countries. Infect Genet Evol (2011) 1.01
Anal and penile high-risk human papillomavirus prevalence in HIV-negative and HIV-infected MSM. AIDS (2013) 1.00
The role of Toll-like receptor-4 in pertussis vaccine-induced immunity. BMC Immunol (2008) 0.99
Characterization of Bordetella holmesii isolates from patients with pertussis-like illness in The Netherlands. FEMS Immunol Med Microbiol (2011) 0.99
Pertussis: a matter of immune modulation. FEMS Microbiol Rev (2011) 0.99
Effect of vaccination on Bordetella pertussis strains, China. Emerg Infect Dis (2010) 0.98
Nasopharyngeal bacterial colonization and gene polymorphisms of mannose-binding lectin and toll-like receptors 2 and 4 in infants. PLoS One (2011) 0.96
An investigation into the cause of the 1983 whooping cough epidemic in the Netherlands. Vaccine (2009) 0.96
Patterns of human papillomavirus DNA and antibody positivity in young males and females, suggesting a site-specific natural course of infection. PLoS One (2013) 0.95
PRELI is a mitochondrial regulator of human primary T-helper cell apoptosis, STAT6, and Th2-cell differentiation. Blood (2008) 0.94
Microarray analysis of response of Salmonella during infection of HLA-B27- transfected human macrophage-like U937 cells. BMC Genomics (2010) 0.93
SNP-based typing: a useful tool to study Bordetella pertussis populations. PLoS One (2011) 0.93
Bordetella pertussis infection is common in nonvaccinated infants admitted for bronchiolitis. Pediatr Infect Dis J (2010) 0.92
Two-component cluster analysis of a large serodiagnostic database for specificity of increases of IgG antibodies against pertussis toxin in paired serum samples and of absolute values in single serum samples. Clin Vaccine Immunol (2012) 0.92
Studies on Prn variation in the mouse model and comparison with epidemiological data. PLoS One (2011) 0.91
The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli. Protein Expr Purif (2005) 0.91
Seroprevalence of antibodies to pertussis and diphtheria among healthy adults in China. J Infect (2011) 0.91
Estimation of household transmission rates of pertussis and the effect of cocooning vaccination strategies on infant pertussis. Epidemiology (2012) 0.90
Enrichment of nucleofected primary human CD4+ T cells: a novel and efficient method for studying gene function and role in human primary T helper cell differentiation. J Immunol Methods (2006) 0.90
Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen. Infect Immun (2004) 0.90
Immunodominance in mouse and human CD4+ T-cell responses specific for the Bordetella pertussis virulence factor P.69 pertactin. Infect Immun (2008) 0.89
Rapid typing of Bordetella pertussis pertussis toxin gene variants by LightCycler real-time PCR and fluorescence resonance energy transfer hybridization probe melting curve analysis. J Clin Microbiol (2002) 0.89
Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis (2004) 0.89
Pertussis before and after the introduction of acellular pertussis vaccines in Finland. Vaccine (2009) 0.89
Gene polymorphism in toll-like receptor 4: effect on antibody production and persistence after acellular pertussis vaccination during adolescence. J Infect Dis (2012) 0.88
Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies. Vaccine (2009) 0.88
Association of Bordetella pertussis with host immune cells in the mouse lung. Microb Pathog (2003) 0.88
EUVAC.NET collaborative study: evaluation and standardisation of serology for diagnosis of pertussis. J Immunol Methods (2011) 0.87
Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection. Vaccine (2012) 0.87
Interactions between Bordetella pertussis and the complement inhibitor factor H. Mol Immunol (2010) 0.87
The association of genetic variants in toll-like receptor 2 subfamily with allergy and asthma after hospitalization for bronchiolitis in infancy. Pediatr Infect Dis J (2014) 0.86
Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis. Vaccine (2006) 0.86
Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009. J Clin Microbiol (2012) 0.86
Toll-like receptor 3 L412F polymorphisms in infants with bronchiolitis and postbronchiolitis wheezing. Pediatr Infect Dis J (2012) 0.86
PFGE and pertactin gene sequencing suggest limited genetic variability within the Finnish Bordetella parapertussis population. J Med Microbiol (2003) 0.85
Antibody responses to defined regions of the Bordetella pertussis virulence factor pertactin. Scand J Infect Dis (2008) 0.85
The effect of HIV infection on anal and penile human papillomavirus incidence and clearance: a cohort study among MSM. AIDS (2016) 0.84
Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice. Clin Vaccine Immunol (2007) 0.83
Appearance of macrolide-resistant Bordetella pertussis strains in China. Antimicrob Agents Chemother (2013) 0.83
C4A deficiency in children and adolescents with recurrent respiratory infections. Hum Immunol (2012) 0.82
Infantile pertussis rediscovered in China. Emerg Infect Dis (2002) 0.82
Bordetella pertussis isolates, Finland. Emerg Infect Dis (2005) 0.81
Whooping cough in Pakistan: Bordetella pertussis vs Bordetella parapertussis in 2005-2009. Scand J Infect Dis (2011) 0.81